University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

4-23-2013

Glycosylate Derivatives of Mithramycin, Method of Preparation
and Uses Thereof
Jürgen Rohr
University of Kentucky, jrohr@uky.edu

Irfan Baig
University of Kentucky, ibaig2@uky.edu

Jose Antonio Salas Fernandez
Alfredo Fernandez Brana
Maria Perez Solares

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Rohr, Jürgen; Baig, Irfan; Fernandez, Jose Antonio Salas; Brana, Alfredo Fernandez; and Solares, Maria
Perez, "Glycosylate Derivatives of Mithramycin, Method of Preparation and Uses Thereof" (2013).
Pharmaceutical Sciences Faculty Patents. 28.
https://uknowledge.uky.edu/ps_patents/28

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

USOO8426169B2

(12) United States Patent

(10) Patent N0.:

Rohr et al.
(54)

US 8,426,169 B2

(45) Date of Patent:

GLYCOSYLATE DERIVATIVES 0F

(58)

Apr. 23, 2013

Field of Classi?cation Search .................. .. 536/41

See application ?le for complete search history.

MITHRAMYCIN, METHOD OF
PREPARATION AND USES THEREOF

(56)

(75) Inventors: Jiirgen Rohr, Lexington, KY (US);
Irfan Baig, Lexington, KY (U S); José
Antonio Salas Fernandez, Oviedo (ES);

References Cited
U.S. PATENT DOCUMENTS

2005/0192432 A1 *

9/2005

Rohr et a1. ................. .. 536/181

Alfredo Fernandez Bra?a, Oviedo

(ES); Carmen Méndez Fernandez,
Oviedo (ES); Maria Pérez Solares,

Oviedo (ES)

OTHER PUBLICATIONS
Lombo et al., The Mithracymin gene cluster of Streptomyces
argillaceus contain a positive regulatory gene and two repeated DNA
sequences that are located at both ends of the cluster, Journal of

(73) Assignees: University of Kentucky Research
Foundation, Lexington, KY (U S);

bacteriology, 1999, vol. 181, p. 642-647.*

(Continued)

Universidad de Oviedo, Oviedo (ES)
(*)

Notice:

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35

U.S.C. 154(b) by 678 days.

Primary Examiner * Elli Peselev

(74) Attorney, Agent, or Firm * TristanA. Fuierer; Moore &

Van Allen, PLLC

(21) Appl. No.:

12/525,695

(57)
ABSTRACT
The present invention provides compounds characterized by

(22)

PCT Filed:

Feb. 4, 2008

(86)

PCT No.:

PCT/ES2008/070015

§ 371 (0X1)’
(2), (4) Date:

the formula (I), Where each of the substituent radicals is
described in the speci?cation. The invention also describes
the use of said compounds in the treatment of various dis
eases, including: cancer or tumoral processes in general, Pag

Nov. 12, 2009

(87) PCTPub.No.: WO2008/096028
PCT Pub. Date: Aug. 14, 2008
(65)

Prior Publication Data

US 2010/0086973 A1

(30)

Apr. 8, 2010

Foreign Application Priority Data
Feb. 6, 2007

(51)

Int. Cl.

(52)

A61K 31/70
C07H 15/00
C12P 19/56
US. Cl.

(ES) ................................. .. 200700378

(2006.01)
(2006.01)
(2006.01)

USPC ............... .. 435/78; 435/886;514/25;536/4.1

et’s disease, hypercalcaemia, hypercalciuria and neurologi
diseases (inter alia, Parkinson’s, Alzheimer’s,

cal

Huntington’ s).

US 8,426,169 B2
Page 2
OTHER PUBLICATIONS

O’Connor, S., Aureolic Acids: Similar Antibiotics with Different

Biosynthetic Gene Clusters, Chemistry & Biology, 2004, pp. 8-10,
International Search Report, PCT/ES2008/070015, Apr. 25, 2008, 2

vol. 11.

pgs.

Chatterjee, S., et al., Sequence-Selective DNA Binding Drugs

Baig, I, et al., Mithramycin Analogues Generated by Combinatorial
Biosynthesis Show Improved Bioactivity, Journal of Natural Prod

Mithramycin A and Chromomycin A3 Are Potent Inhibitors of
Neuronal Apoptosis Induced by Oxidative Stress and DNA Damage
in Cortical Neurons, Annals ofNeurology, Mar. 2001, pp. 345-354,
vol. 49, No. 3.

ucts, 2008, pp. 199-207, vol. 71.
Fernandez Lozano, M. Jose, et al., Characterization of Two

Polyketide Methyltransferases Involved in the Biosynthesis of the

Antitumor Drug Mithramycin by Streptomyces argillaceus, The
Journal ofBiological Chemistry, 2000, pp. 3065-3074, vol. 275, No.
5.

Adams, V., et al., New Anti-tumor Mithramycins with Altered Sac
charide Chain through Combinatorial Biosynthesis, 2005 AAPS

Annual Meeting and Exposition, Nov. 2005, Abstract Only.

Lombo, F., et al., Engineering Biosynthetic Pathways for
Deoxysugars: Branched-Chain Sugar Pathways and Derivatives from
the Antitumor Tetracenomycin, Chemistry & Biology, 2004, pp.
1709-1718, vol. 11.
Shashkov, A.S., et al., Structure of an antitumor antibiotic

variamycin, Bioorganicheskaya Khimiya, 1991, pp. 410-416, vol.
17, No. 3, Abstract Only.
* cited by examiner

US. Patent

Apr. 23, 2013

US 8,426,169 B2

Sheet 2 0f 4

on

comlv

\<
25:5m08w

um.0:

sea3Q
+

Aw/>3_Am6ZE|_aV ENgbiv

Ni
2555m:50 ,1

.52
$00
E.m

..ou
,0F.
c

Gm.DE

(/vwd.

_.m5aEu?2mk .

1‘!8.10
26

_“
_n2. 7

ml:
“NvwPM
B.m
2.
w

a. meva

m
.11
_

{A
b42.J.?-

06

mod

i)

EtaP
\

2.5:8
m \<
.?

.F,_ On
ON
Ow

.52 Om.UE

E4/

<m.UE mg5qNu 2

:55m.3

NQS5HE
$6

ohd

Dad.

nv

"Nd

06

352.

US. Patent

Apr. 23, 2013

Sheet 3 0f4

US 8,426,169 B2

FIG. 4a

Me

0

R O

(VIII) R|-

Me
O

Rl?on/ \
B

0 R180 Me

R 0

R2=

16

o

(l')

OR17E

D

00

0
0

(VI)

Me

Me
(IX

)

R =

1

190

0
\

R100

R110

O

Me

R200 R210

B

Me

E

D

Me

Me

(X) R1

=

R

O

0

R1120

B

)

O

'le

‘

Me
(XI)

R 1 = OH

(III)

OR13 D

R2 =

R220
Me

R240 Me
0

O

ORZBE

Me
_

(XII) R1: H

R2_

D

0 R240 Me

O

R22Me

O
0st E

Me

(XIII) R1: R1OOm/O\
R110

D

R140Me

R2=

(W)

R150 k0

D

(VII)

US. Patent

Apr. 23, 2013

Sheet 4 0f4

US 8,426,169 B2

FIG 4b

0R7 0R8 0
Me
R40
0

(1)

R20

Me

R240

RIOOm/O\

(XVII) R1:

R110

5

H
U

R2

-

M8 0

R250 D

(X'V)

R240Me
R2-

(XVIII) R1: H

Me

(XIX)

R10?D Sig/CK

R1:

‘1

B

0
R250 D

(XIV)

Me

Me

OR 0

R2= RZGOwao§£ /

01)

OR27 E

Me

(XX)

R1 = H

RT R260

D

Me

OR288E20
0R27 E

R o

(XXI) EU

H

(xv)

Me

0

R o

D

(XV)

Me

I

OR3° E

D

(XVI)

US 8,426,169 B2
1

2

GLYCOSYLATE DERIVATIVES OF

MITHRAMYCIN, METHOD OF

charide, whereas glycosyltransferases thGI and thGII
catalyze the formation of the disaccharide. Finally, the cleav

PREPARATION AND USES THEREOF

age of one of the rings, followed by the reduction of a keto

CROSS-REFERENCE TO RELATED
APPLICATIONS

group in the side chain, generates MTM.
There is currently a great need for novel antitumor agents,
with improved activity, with fewer undesirable side effects

and with higher selectivity, compared to currently used drugs.
Traditionally, the pharmaceutical industry has developed

This application is ?led under the provisions of 35 U.S.C.
§371 and claims the priority of International Patent Applica

novel drugs by means of two main routes: (1) search for novel
natural products, and (2) chemical modi?cation and/or syn
thesis of certain compounds. These methods are still useful,
but usually require very important investments of resources
(time, money, energy), since it is normally necessary to ana
lyze thousands of products in order to ?nd a novel promising

tion No. PCT/ES2008/070015 ?led on 4 Feb. 2008 entitled

“Glycosylate Derivatives of Mithramycin, Method of Prepa
ration and Uses Thereof” in the name of Jurgen Rohr, et al.,

which claims priority of Spanish Patent Application No.
P200700378 ?led on 6 Feb. 2007, both of which are hereby

incorporated by reference herein in their entirety.

compound. The development of recombinant DNA technol

The invention belongs to the pharmaceutical ?eld and spe

ogy has opened up an interesting ?eld of research for the
generation of novel bioactive compounds by means of the
manipulation of genes involved in the biosynthesis of antitu
mor agents, mainly of bacteria of the actinomycete group

ci?cally relates to compounds with application in oncology,
with a chemical structure derived from mithramycin and

which are obtained by microorganism fermentation.
20

STATE OF THE ART

Mithramycin (MTM) is an antitumor drug produced by
microorganisms of the Streptomyces genus, including Strep
tomyces argillaceus ATCC 12956. This drug is the most
important representative of the group of aureolic acid, and it
is used for the treatment of testicular carcinoma, Paget’s
disease and hypercalcaemia caused by bone lesions associ
ated to cancer (Oncology 1973, 28,147-163; Biochem. Bio
phys. Res. Commun. 1993, 195, 1245-1253; Treat. Endo
crinol. 2002, 1, 241-257; Treat. Endocrinol. 2003, 2, 273
292). MTM is furthermore a neuroprotective agent which
could be useful for the treatment of neurological diseases
such as stroke, amyotrophic lateral sclerosis, Parkinson’s dis
ease, Huntington’s disease, multiple sclerosis and viral

25

30

35

and are useful for obtaining derivatives of MTM (US 2005/
0192432 A1 ; J. Am. Chem. Soc. 2003, 125, 5745-5753; J. Am.
40

mycinA3, olivomycinA, UCH9 and duramycin (Appl. Micro
biol. Biotechnol. 2006, 73, 1-14). All ofthem contain a tricy

compounds have 4-6 deoxysugars linked in the form of trisac
charide or tetrasaccharide (at carbon 2) and monosaccharide
or disaccharide (at carbon 6). Aureolic acid compounds differ
in the nature and linking of their saccharide chains, contain
ing different 2,6-dideoxysugars. These structural variations
are responsible for the subtle differences existing among the
members of the group as regards their DNA binding and their

45

50

ceus M7U1, which was obtained from Streptomyces argilla
ceus by means of the inactivation of the mth gene (Mol.

Gene. Genet. 2001, 264, 827-835). The mth gene encodes

55

section (b) is Streptomyces argillaceus M7W1, which was
obtained from Streptomyces argillaceus by means of the inac
tivation of the mth gene (US 2005/0192432 A1; J. Am.
Chem. Soc. 2003, 125, 5745-5753). The mth gene encodes

60

tion of demycarosyl-MTM-SK, MTM-SA, MTM-SDK, and

biological activity (Biopolymers 2000, 54, 104-114). There
fore, obtaining novel derivatives of MTM with altered glyco
sidic patterns can generate drugs with improved activity.
The cluster of genes responsible for MTM biosynthesis has
been widely studied (Appl. Microbiol. Biotechnol. 2006, 73,

Chem. Soc. 2002, 124, 1606-1614; Mol. Gene. Genet. 2001,
264, 827-835; FEMSMicrobiol. Lett. 2000, 186, 61-65; Mol.
Gene. Genet. 2000, 262, 991-1000;J. Biol. Chem. 2000, 275,
3065-3074; Mol. Gene. Genet. 1999, 261, 216-225; Chem.
Biol. 1999, 6, 19-30; J. Bacteriol. 1999, 181, 642-647; J.
Bacteriol. 1998, 180, 4929-4937; J. Bacteriol. 1997, 179,
3354-3357; Mol. Gene. Genet. 1996, 251, 692-698; Gene
1996, 172, 87-91). An example of strain of section (b), which
can be used in the present invention, is Streptomyces argilla

a 4-ketoreductase involved in D-oliose biosynthesis, and its
inactivation results in the accumulation of premithramyci
none and premithramycin A. Another example of strain of

biological activity pro?le. It is well known that the glycosy
lation pattern of antitumor drugs which act by binding to
DNA, as is the case of MTM, is very important in their

The present invention provides novel bacterial strains
derived from Streptomyces argillaceus. These strains are
obtained by means of introducing certain additional nucleic
acids in existing bacterial strains, which can be: (a) Strepto
myces argillaceus, or (b) strains derived from Streptomyces
argillaceus. The strains of section (b) can be obtained (among
other methods) by means of the inactivation of one (or sev

eral) of the genes responsible for mithramycin biosynthesis,

The chemical structure of MTM is shown in FIG. 1. The

clic core with a polyketide origin, with a highly
functionalized side chain at carbon 3. The residue at carbon 7
can be a hydrogen atom or a short-chain alkyl. Likewise, these

techniques can also be used to improve the production of
already known natural compounds, since natural strains usu
ally produce low concentrations of the metabolite of interest.
DESCRIPTION OF THE INVENTION

encephalitis (J. Neurosci. 2004, 24, 10335-10342; J. Biol.
Chem. 2006, 281, 16672-16680). Furthermore, MTM has
antibiotic activity (Antibiot. Chemother. 1962, 12, 182-186).
group of aureolic acid compounds includes MTM, chromo

(Trends Biotechnol. 2001, 19, 449-456; J. Mol. Microbiol.
Biotechnol. 2005, 9, 77-85; Curr. Opin. Drug Discov. Devel.
2005, 8, 748-756; J. Ind. Microbiol. Biotechnol. 2006, 33,
560-568; Curr. Opin. Microbiol. 2006, 9, 252-260). These

a ketoreductase, and its inactivation results in the accumula

1-14). MTM biosynthesis in Streptomyces argillaceus

MTM-SK.

includes the condensation of 10 units of acyl-coenzyme A to

The introduction of nucleic acids in Streptomyces argilla

generate a tetracyclic intermediate, called premithramyci
none (FIG. 2). Then, 5 units of deoxysugars are successively

ceus (or in derivative strains) can be carried out by means of

added, tetracyclic intermediates with 3 sugars and with 5

sugars being generated. The glycosyltransferases thGIII
and thGIV are responsible for the formation of the trisac

65

protoplast transformation, conjugation, or other known meth
ods (such as those described in Practical Streptomyces genet
ics, The John Innes Foundation, Norwich, Great Britain,
2000), such that the nucleic acids are replicable in the organ

US 8,426,169 B2
3

4

ism, either in the form of an extrachromosomal element or

R2 is hydrogen, a protecting group, a monosaccharide of

integrated in the chromosome of the organism. Said nucleic
acids encode enzymes for the biosynthesis of different sugars;

formula (III),

said sugars are not normally produced by Slreplomyces
argillaceus. Examples of nucleic acids useful for the present
invention are those contained in the following plasmids
(which are mentioned by way of example): pLNBlV (Chem.
Biol. 2002, 9, 721-729; J Nat. Prod. 2002, 65, 1685-1689),

(111)

Me

pRHAM (J. Mol. Microbiol. Biotechnol. 2000, 2, 271-276),
pLN2 (Chem. Biol. 2002, 9, 721-729), pLNR (Chem. Biol.
2002, 9, 721-729), and pFL845 (Chem. Commun. (Camb).
2005 Mar. 28; (12): 1 604-6). The mentioned plasmids contain
nucleic acids encoding enzymes for the biosynthesis of the
following sugars (in the form of NDP derivatives), respec

tively: L-digitoxose, L-rhamnose, L-olivose, D-olivose, and

(1V)

D-amicetose. However, other nucleic acids which encode
enzymes for the biosynthesis of other unmentioned sugars
can be used in the present invention.
The bacterial strains of this invention can be cultured in any

20

suitable medium, in conditions allowing their growth, as is
described in Gene 1996, 172, 87-91; J. Bacteriol. 1998, 180,
4929-4937; J. Am. Chem. Soc. 2003, 125, 5745-5753. After
several days of incubation, these cultures contain a high
amount of cells (mycelium), together with a mixture of com
pounds, including derivatives of MTM. The cultures are then

25

subjected to processes for the separation of a liquid phase
(supernatant) and a solid phase (mycelium). The two phases
are then subjected, separately, to several processes which can

R180

Me
O

16

R O

(V)
Me
O

0%

30

include extraction with several organic solvents, and several

types of chromatography (such as HPLC, high performance
liquid chromatography), for the purpose of obtaining the

a disaccharide of formula (V1),

derivatives of MTM in the form of pure compounds. The
derivatives of MTM are antitumor agents and also act as

35

neuroprotective agents.

(V1)

Me

Likewise, the present invention provides compounds char
acterized by the following formula (I):
Me

R O
20

Me

‘0

or a disaccharide of formula (V11).

R240

Me

R220Me

O

(V11)
Me

0%

OR23

wherein

55

R1 is hydrogen, hydroxyl (OH), a hydroxyl group protected

a monosaccharide of formula QilV),

with a protecting group, a monosaccharide of formula (ll)

(11)

60

R O
24

(XIV)
M6

0

65

R250

US 8,426,169 B2
6

5

R9 is hydrogen, a methyl group, or an alkyl group; and
the stereochemistry of carbons a, b, c, d and e is R, S or a
mixture of both.

a disaccharide of formula C(V),

Me

Me

The protecting group can consist of an alkyl group, a

(XV)

cycloalkyl group, a heterocyclic cycloalkyl group, a hydroxy
alkyl group, a halogenated alkyl group, an alkoxyalkyl group,
an alkenyl group, an alkynyl group, an aryl group, a hetero
cyclic aryl group, an alkylaryl group, an ester group, a car
bonate group, a carboxylic acid group, an aldehyde group, a
ketone group, a urethane group, a silyl group, a sulfoxo group

OR27

or a combination thereof.

or a disaccharide of formula (XVI)

Me

Me

The compounds of formula (I) include those Wherein:
R3, R4, R5 and R6 are hydrogen; or
R3, R4, R5, R6, R7 and R8 are hydrogen; or
R9 is methyl; or

(XVI)

the stereochemistry at carbons a, b, c and d is S, and the
stereochemistry at carbon e is R; or

Me

R3: R4, R5, R6, R7, R8: R10, R11, R12, R13, R14, R15, R16,
R17: R18: and R19: R20: R21: R22: R23: R24: R25: R26: R27: R28:

OR30
20

R29, R30, R3 1 are hydrogen, R9 is methyl, the stereochemistry
at carbons a, b, c and d is S, and the stereochemistry at carbon

R3: R4: R5: R6: R7 and R8: R10: R11: R12: R13: R14: R15: R16:
R17, R18: R19, R20, R21, R22, R23 and R24, R25, R26: R27, 28,

e is R.

R29, R30, R31 are each and independently hydrogen or a pro

In particular, the present invention provides, among others,
the compounds With the following formulas (VIII, IX, X, XI,

tecting group;

XII, XIII):
(VIII)

(1X)

HO
Me
OH

US 8,426,169 B2
-continued
(X)
Me

HO

Me
M

6

O

HO

HO
Me

O

0

OH

(X1)
Me

How/0
HO

Me
Me
HO
Me

HO Me
O

O

HO
O

O
0

OH

(X11)
Me

PIG/Ev
HO

Me

HOMe

O
HO
O

0

HO

(XIII)

HO
HO
Me

O

O
O

0
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-continued
(XVII)

(XVIII)

Me
HO M6

0
HO
O

0

OH

(XIX)
Me

How
HO

(U)

HO
HO

O

HO

O
O

O
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12
-continued
09(1)

HO

OH

example, mice, rabbits, guinea pigs, etc.) and birds. The sub

The compounds of the invention are tumor growth inhibi
tors and are therefore useful in the treatment of cancer.

20

preferably, a human being.

Thus, the pharmaceutical compositions comprising an

In general, an “effective amount” of a compound is that
amount necessary to achieve the desired result. For example,
the effective amount of a compound of the present invention

effective amount of a compound of formula I or a pharma

ceutically acceptable salt or solvate thereof together with a

pharmaceutically acceptable excipient are object of the
present invention.

25

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

treats the cancer by inhibiting the growth of the cells forming
the tumor, thereby preventing invasion of normal tissues and
blood/lymph vessels by the tumor cells and, therefore pre
venting metastasis. Examples of cancers that can be treated

medicinal product is also object of the present invention.

include, but are not limited to, lung, colon, ovarian, prostate,
testicular, melanoma, kidney, breast, central nervous system
and leukemia. The expression “acceptable pharmaceutical
composition” consists of a biologically suitable material, i.e.,

The use of a compound of formula I or a pharmaceutically

acceptable salt or solvate thereof for inhibiting the growth of
a tumor is also object of the present invention.

As used herein, “inhibiting” means decreasing, slowing

the material may be administered to the subject without caus

down or stopping. Therefore, a compound of this invention
can decrease, slow down or stop the growth of a tumor cell. As

ject is preferably a mammal such as a primate, and, more

ing substantially deleterious biological effects.

used herein, “growth” means increase in size or proliferation

The doses or amounts of the compounds of the invention
must be suf?ciently large to cause the desired effect. How

or both. Therefore, a compound of this invention can inhibit
the size increase of a tumor cell and/ or can prevent the tumor

effects, for example unwanted cross-reactions, anaphylactic

cell from dividing and the number of tumor cells from
increasing. A “tumor cell” is a cell forming a neoplasm (new

35

ever, the dose must not be so large that it causes adverse side

40

reactions, and the like. Generally, the dose will vary with age,
condition, sex and the degree of disease of the subject, and can
be determined by any person skilled in the art. The dose can

growth), which can be cancerous (malignant) or non-cancer
ous (benign). A cancerous tumor cell can invade the normal

normal tissues but cannot invade normal tissues and blood/
lymph vessels and cannot form metastases in tissues far from

be adjusted by each physician, based on the clinical condition
of the subject involved. The dose, dosing regimen and route of
administration can be varied. The doses and the dosing regi
men currently used for MTM provide a guideline for the
doses and dosing regimen that can be used for the novel
derivatives of MTM (see for example Cancer Treal. Rep.

the original tumor.

1979, 63, 1835-1838; Ann. Intern. Med. 1975, 83, 659-660).

tissues around it and blood/lymph vessels and form
metastases in tissues far from the original tumor. In contrast,
a non-cancerous tumor cell can grow and compress adjacent 45

The use of a compound of formula I or a pharmaceutically

acceptable salt or solvate thereof for treating cancer is also

50

object of the present invention.

medicinal product for the treatment of Paget’s disease is also
object of the present invention.
A method for treating a subject, including a human being,

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

medicinal product with antitumor activity is also object of the
present invention.

diagnosed with Paget’s disease, consisting of treating said
55

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

medicinal product for the treatment of cancer is also object of
the present invention.
A method for treating a subject, including a human being,

60

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

medicinal product for the treatment of hypercalcaemia is also
object of the present invention.
A method for treating a subject, including a human being,

with a therapeutically effective amount of a compound of
formula I or a pharmaceutically acceptable salt or solvate is

also object of the present invention.
As used herein, a “subject” can include domesticated ani

subject with a therapeutically effective amount of a com
pound of formula I or a pharmaceutically acceptable salt or

solvate is also object of the present invention. The subject can
be a mammal, preferably a human being, and the compound
can be, among other routes, parenterally administered.

diagnosed with cancer, consisting of treating said subject

mals (for example, cats, dogs, etc.), livestock (for example,
cows, horses, pigs, sheep, goats, etc.), laboratory animals (for

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

65

diagnosed with hypercalcaemia, consisting of treating said
subject with a therapeutically effective amount of a com
pound of formula I or a pharmaceutically acceptable salt or

US 8,426,169 B2
13

14

solvate is also object of the present invention. The subject can
be a mammal, preferably a human being, and the compound
can be, among other routes, parenterally administered.

Examples of non-aqueous solvents are: propylene glycol,
polyethylene glycol, vegetable oils such as olive oil, and
injectable organic esters such as ethyl oleate. Examples of
aqueous solvents are: water, alcoholic-aqueous solutions,
emulsions or suspensions, including saline and buffered solu
tions. Examples of parenteral vehicles are: sodium chloride

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

medicinal product for the treatment of hypercalciuria is also
object of the present invention.
A method for treating a subject, including a human being,

solution, Ringer’s dextrose, dextrose and sodium chloride,
etc. Preservatives and other additives such as, for example,

diagnosed with hypercalciuria, consisting of treating said

antimicrobial agents, anti-oxidants, chelating agents, inert

subject with a therapeutically effective amount of a com

gases, etc may also be present. Formulations for topical

pound of formula I or a pharmaceutically acceptable salt or

administration may include creams, lotions, gels, drops, sup
positories, sprays, liquids and powders. Certain conventional

solvate is also object of the present invention. The subject can
be a mammal, preferably a human being, and the compound
can be, among other routes, parenterally administered.

pharmaceutical carriers, aqueous, oily or powder bases,
thickeners, etc. may also be necessary or desirable. Compo
sitions for oral administration may include powders or gran
ules, suspensions or solutions in water or non-aqueous

The use of a compound of formula I or a pharmaceutically
acceptable salt or solvate thereof in the manufacture of a

medicinal product for the treatment of neurological diseases
is also object of the present invention.
A method for treating a subject, including a human being,

diagnosed with a neurological disease, consisting of treating

medium, capsules or tablets. The inclusion of thickeners,

?avorings, diluents, emulsi?ers, dispersants, etc. may be
20

said subject with a therapeutically effective amount of a com
pound of formula I or a pharmaceutically acceptable salt or

solvate is also object of the present invention. The subject can
be a mammal, preferably a human being, and the compound
can be, among other routes, parenterally administered.
Examples of neurological diseases that can be treated
include, but are not limited to, neurodegenerative diseases

preted as a compound covered by the general formula I.
Likewise, the term “prodrug” of mithramycin must be inter
preted, for the purposes of the present invention and of the
25

description thereof, as any compound releasing mithramycin
or a derivative, according to general formula I, thereof when
it circulates in blood or enters the cell.

such as Parkinson’ s, Alzheimer’s, and Huntington’ s diseases.
The compounds of the invention can be useful for the

research in biochemistry or cell biology. For example, the
compounds can be useful for blocking the expression of c-Src
(and other Spl-dependent enzymes) in osteoclasts or other
cell types.
Any of the compounds of the invention can be therapeuti
cally used forming part of an acceptable pharmaceutical com
position. Any person skilled in the art can create acceptable
pharmaceutical compositions, which may consist of sterile

desirable.
For the purposes of the present invention and its descrip
tion, the term “derivative” of mithramycin must be inter

30

Description of a Preferred Embodiment
The following examples, described in detail, are set forth in
order to better understand the present invention, which
examples must be understood without a limiting character for
the scope of the invention.
EXAMPLE 1

35

Obtaining the Bacterial Strain Slreplomyces

argillaceus (pLNBIV)

water solutions, saline solutions, or buffered solutions at

physiological pH. Any of the compounds of the invention can
be prepared in the form of pharmaceutical composition. The
pharmaceutical compositions may include several carrier

40

ces argillaceus ATCC 12956. The introduction of the plasmid
was carried out by means of protoplast transformation, fol

agents, thickeners, diluents, buffers, preservatives, surfac
tants, and others, in addition to the compound of the inven
tion. The pharmaceutical compositions may also include
active ingredients such as antimicrobial agents, anti-in?am
matory agents, anesthetic agents, etc.

lowing standard procedures (Kieser et al., Practical Strepto
myces genetics, The John Innes Foundation, Norwich, Great
45

synthesis of nucleosidyl diphosphate (NDP)-L-digitoxose
(Chem. Biol. 2002, 9, 721-729; J. Nat. Prod. 2002, 65, 1685
1689). The strain Slreplomyces argillaceus (pLNBIV) was
50

deposited on 15 Nov. 2006 in the Coleccion Espanola de

Cultivos Tipo (CECT) [Spanish Type Culture Collection],
Universidad de Valencia, Campus de Burjassot, 46100 Bur
jassot (Valencia, Spain) with accession number CECT 3384.

more, a compound can be administered to a subject vaginally,

rectally, intranasally, orally, by inhalation, or parenterally, by
intradermal, subcutaneous, intramuscular, intraperitoneal,
intrarectal, intra-arterial, intralymphatic, intravenous,

Britain, 2000). Plasmid pLNBIV has been previously
described, and contains a series of genes encoding the bio

The compounds of the invention can be administered to the
subject in several different ways depending on whether the
treatment is to be local or systemic, and depending on the area

to be treated. Thus, for example, a compound of the present
invention can be administered in the form of ophthalmic
solution, for application in the surface of the eye. Further

The strain Slreplomyces argillaceus (pLNBIV) was gener
ated by means of introducing plasmid pLNBIV in Streptomy

55

EXAMPLE 2

intrathecal and intratracheal routes. Parental administration,

Production of demycarosyl-3D-[3-D-digitoxosyl

if used, is generally carried out by means of injection.
Inj ectables can be prepared in different forms, such as liquid
solutions or suspensions, solid forms suitable for being dis

60

MTM (formula VIII), deoliosyl-3C-0t-L-digitoxosyl
MTM (formula IX), deoliosyl-3C-[3-D-mycarosyl
MTM (formula X), and 3A-deolivosyl-MTM

(formula XI)

solved or suspended prior to injection, or as emulsions. Other
forms of parenteral administration use slow or sustained
release systems, such that a constant dose is maintained (see,

For the puri?cation of the derivatives of MTM, the strain S.
argillaceus (pLNBIV) was cultured in R5A medium using a

for example, U.S. Pat. No. 3,710,795). Preparations for
parenteral administration include sterile aqueous or non

65

two-step culture method, as has been previously described (J.

aqueous solutions, suspensions, and emulsions which may

Bacteriol. 1998, 180, 4929-4937). In the production step,

further contain buffers and diluent additives and others.

eight 2 L Erlenmeyer ?asks were used, each of them contain

US 8,426,169 B2
15
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ing 400 ml of medium, which were incubated for 5 days. The

(relative intensity): 1093 (100) [M+Na], 1109 (11) [M+K],
833 (7) [M+H-{Sugar 1A and 1B}+Na], 811 (16) [M+H

cultures were centrifuged and ?ltered, and the broth was
extracted in solid phase as has been described (Chem. Biol.

Sugar 1A and 1B], 681 (14) [M+H-Trisaccharide], 421 (18)
[M+H-Tri- and disaccharide]. HR-FAB m/z [M+Na+]: calcu
lated, 1093.4467; obtained, 1093.4447. UV/Vis (Methanol)
kmax (e): 412 (1532), 317 (1663), 279 (5112), 229 (5042)

2002, 9, 519-531). The obtained fractions were analyzed by
HPLC-MS using chromatographic equipment coupled to a
ZQ4000 mass spectrometer (WatersiMicromass), using as
solvents acetonitrile and 0.1% tri?uoroacetic acid (TFA) in
water, and a reversed-phase column (Symmetry C18, 2.1><

nm. IR (KBr) v: 3420 (OH), 2920 (CH), 2848 (CH), 1716

150 mm, Waters). The samples were eluted with 10% aceto
nitrile for the ?rst 4 minutes, followed by a 10-88% acetoni
trile linear gradient for 26 minutes, at a ?ow of 0.25 ml/min.
Detection and spectral characterization of the peaks was car
ried out with a photodiode detector and Empower software
(Waters). The MS analyses were carried out by means of

Table 1 shows the 1H-NMR and 13 C-NMR data.

(C:O), 1631 (C:O), 1514(C:C),1382, 1130,1064 cm“.
NMR and MS analysis of deoliosyl-3C-0t-L-digitoxosyl

MTM (formula IX), C52H76Oz4. Negative ESI-MS m/z (rela
tive intensity): 1083 (100) [M—H], 1119/1121 (26) [M+Cl‘].
Positive ESI-MS m/z (relative intensity): 1107 (100)

tions containing derivatives of MTM (which eluted between

[M+Na+], 1123 (13) [M+K+], 847 (5) [M+H-{Disaccha
ride}+Na], 825 (27) [M+H-Disaccharide], 681 (11) [M+H
Trisaccharide], 551 (34) [M+H-Sugars 1A, 1B, 1D and 1E]

45 and 55 minutes) were pooled and dried under vacuum.

and 421 (22) [M+H-Tri- and disaccharide]. HR-FAB m/z

positive-mode electrospray ionization, with a capillary volt
age of 3 kV and cone voltages of 20 and 100 V. Those frac

[M+Na+]: calculated, 1107.4603; obtained, 1107.4624.

This extract was redissolved and chromatographed in a

uBondapak C18 radial compression column (PrepPak Car

20

(6851), 230 (6420) nm. IR (KBr) v: 3409 (OH), 2924 (CH),

tridge, 25><100 mm, Waters). An isocratic elution with a mix
ture of acetonitrile and 0.1% TFA in water (42:58) at 10
ml/min was used. Demycarosyl-3D-[3-D-digitoxosyl-MTM
and 3A-deolivosyl-MTM were repuri?ed in a semiprepara

tive column (Symmetry C18, 7.8><300 mm, Waters) with iso

UV/Vis (Methanol) kmax (e): 412 (2148), 317 (2491), 278

2850 (CH), 1716 (C:O), 1634 (C:O), 1514 (C:C), 1374,
1126, 1064 cm_l. Table 2 shows the 1H-NMR and l3C-NMR
data.
25

NMR and MS analysis of deoliosyl-3C-[3-D-mycarosyl

cratic elution with acetonitrile and 0.1% TFA in water (37:

MTM (formula X), C46H66OZI. Negative ESI-MS m/z (rela

63), at 3 ml/min. Deoliosyl-3C-(x-L-digitoxosyl-MTM and
deoliosyl-3C-[3-D-mycarosyl-MTM were also repuri?ed
using the same column and the same solvents, but changing

tive intensity): 953 (100) [M—H]. Positive ESI-MS m/z (rela
tive intensity): 977 (100) [M+Na+], 993 (5) [M+K+], 695 (8)
[M-Sugar 1A and 1B], 681 (10) [M-Sugar 1C and 1D] and
421 (20) [M+H-bis-disaccharide]. HR-FAB m/z [M+Na+]:
calculated, 977.3745; obtained, 977.3948. UV/Vis (Metha
nol) kmax (e): 412 (1357), 316 (1629), 278 (3274), 230

the mixture to 45:55. In all cases, after each puri?cation step,
the collected compounds were diluted 4 times with water and

30

desalted and concentrated by means of solid-phase extrac
tion, in order to be ?nally lyophilized. Thus, 14.3 mg of

(2982) nm. IR (KBr) v: 3425 (OH), 2924 (CH), 2850 (CH),

demycarosyl-3D-[3-D-digitoxosyl-MTM (formula VIII), 5.8
mg of deoliosyl-3C-(x-L-digitoxosyl-MTM (formula IX), 3.3
mg of deoliosyl-3C-[3-D-mycarosyl-MTM (formula X), and

1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1122, 1064
35

NMR and MS analysis of 3A-deolivosyl-MTM (formula

10.9 mg of 3A-deolivosyl-MTM (formula XI) were obtained.

XI), C46H66OZI. Negative ESI-MS m/z (relative intensity):
953 (100) [M—H], 989/991 (9) [M+Cl‘], 823 (5) [M-Sugar

The products were characterized by means of NMR spec

troscopy and mass spectrometry. The electrospray ionization
mass spectra (ESI-MS) were acquired using a Thermo Finni
gan LCQ mass spectrometer, with sample introduction by
direct diffusion. The high-resolution positive-mode fast atom
bombardment (FAB) mass spectrometry was acquired using a

VG70SQ model mass spectrometer (with double-focusing
magnetic sector). The pseudomolecular ion MS-MS spec

40
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the fragmentation pattern of the molecule. The UV spectra

[M+H-Sugar 1A and 1B], 681 (25) [M+H-Sugar 1C and 1D],
551 (50) [M+H-Sugars 1A, 1B and 1D] and 421 (33) [M+H
Tri- and monosaccharide]. HR-FAB m/z [M+Na+]: calcu
lated, 977.3735; obtained, 977.3950. UV/Vis (Methanol)
kmax (e):412 (2178), 316 (2310), 278 (8099), 231 (7363)nm.
IR (KBr) v: 3421 (OH), 2924 (CH), 2850 (CH), 1716 (C:O),
1634 (C:O), 1514 (C:C), 1374, 1122, 1060 cm_l. Table 4
shows the 1H-NMR and l3C-NMR data.

50

pyridine d5, using a 400 MHz Varian Inova instrument,
except the 13C broadband spectra, which were obtained at
50.3 and 75.4 MHz in 200 and 300 MHz Varian Inova spec
trometers, respectively. The 6 values were adjusted with ref
erence to the solvent peaks (6 8.74 ppm and 6 150.35 ppm for

1B], 809 (8) [M+H-Sugar 1D]. Positive ESI-MS m/z (relative
intensity): 955 (100) [M+Na+], 993 (10) [M+K+], 833 (13)

[M+H-{Sugar1D}+Na+],825 (11) [M+H-Sugar1B], 695 (5)

trometry was performed in both +ve and —ve modes to study
were obtained with a Varian CARY 50 spectrometer, and the
IR spectra were obtained from KBr discs in a Nicolet Magna
IR-560 spectrometer. All the NMR data were obtained in

cm_l. Table 3 shows the 1H-NMR and 13 C-NMR data.

EXAMPLE 3

Obtaining the Slreplomyces argillaceus (pFL845)
Bacterial Strain
55

1H and 13C NMR, respectively). All the NMR assignments
are based on 1H and 13C spectra using 1H, l3C-HSQC and

The strain Slreplomyces argillaceus (pFL845) was gener
ated by means of introducing plasmid pFL845 in Streptomy

CIGAR-HMBC spectra, 1H, lH-DQ-COSY and NOESY

ces argillaceus. The introduction of the plasmid was carried

spectra, which allowed the unambiguous assignment of all

out by means of protoplast transformation, following stan

NMR signals. Demycarosyl-3D-[3-D-digitoxosyl-MTM (for
spectra to separately identify the spin patterns of the sugars.

dard procedures (Kieser et al., Practical Slreplomyces genet
ics, The John Innes Foundation, Norwich, Great Britain,
2000). Plasmid pFL845 has been previously described, and

The chemical structure of the compounds is shown in FIG. 4.

contains a series of genes encoding the biosynthesis of nucle

60

mula VIII) was furthermore studied by means of 1D-TOCSY

NMR and MS analysis of demycarosyl-3D-[3-D-digitoxo

syl-MTM (formula VIII), C51H74OZ4. Negative ESI-MS m/z
(relative intensity): 1069 (100) [M—H], 1105/1107 (22)
[M+Cl'], 939 (7) [M—H-Sugar 1A]. Positive ESI-MS m/z

osidyl diphosphate (NDP)-D-amicetose (Chem. Commun.
65

(Camb). 2005 Mar. 28; (12): 1 604-6). The strain Slreplomyces
argillaceus (pFL845) was deposited on 15 Nov. 2006 in the

Coleccion Espanola de Cultivos Tipo (CECT) [Spanish Type

US 8,426,169 B2
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Culture Collection], Universidad de Valencia, Campus de
Burj assot, 46100 Burjassot (Valencia, Spain) with accession

2000). Plasmid pFL942 has been previously described, and
contains a series of genes encoding the biosynthesis of nucle

osidyl diphosphate (NDP)-L-mycarose (Chemistry & Biol
ogy. 2004, (11):1709-18). The strain Slreplomyces argilla

number CECT 3383.
EXAMPLE 4

ceus (pFL942) was deposited on May 2, 2008 in the

Coleccion Espa?ola de Cultivos Tipo (CECT) [Spanish Type
Production of demycarosyl-MTM (formula XII) and

Culture Collection], Universidad de Valencia, Campus de
Burjassot, 46100 Burj assot (Valencia, Spain) with accession

6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula
XIII)

number CECT 7368.

To purify the novel derivatives of mithramycin produced
by S. argillaceus (pFL845), this strain was cultured in eight 2
L ?asks containing 400 ml of R5A medium supplemented
with thiostrepton (5 p1ng f.c.). After 6 days of incubation at

EXAMPLE 6

Production of deoliosyl-demycarosyl-3C-[3-D-boivi

nosyl-MTM (formula XVII) and demycarosyl-3D-[3
D-digitoxosyl-MTM (formula VIII)

30° C., the cultures were centrifuged, ?ltered and a solid
phase extraction was carried out. The extract was then sub

jected to a ?rst chromatography using a uBondapak C18

To purify the novel derivatives of mithramycin produced

cartridge. The elution was carried out at 10 ml/min using a
mixture of acetonitrile and TFA in water (42:58) as a mobile
phase. A second chromatography was then carried out in

by S. argillaceus (pFL942), this strain was cultured in R5A
solid medium. 100 Agar plates were uniformly inoculated
with spores and after 6 days of incubation at 28° C., the

20

Symmetry C18 (7.8><300), at 3 ml/min using a mixture of
acetonitrile and TFA in water (37:63, for 845-1 P1; 42:58, for
845-1 P3) as a mobile phase. The following yield was

obtained: 16.1 mg of demycarosyl-MTM (formula XII) and
4.3 mg of 6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula
XIII). The products were characterized by HPLC-MS, as
described in Example 2.
NMR and MS analysis of demycarosyl-MTM (formula

XII), C45H64OZI. Amorphous yellow solid. [0t]st —25 (c
0.032, MeOH); Negative ESI-MS m/z (relative intensity):

25

30

939 (100) [M—H], 975/977 (28) [M+Cl‘], 809 (10) [M—H

{sugarA}], 679(5) [M—H-{Disaccharide}]. Positive ESI-MS
[M+K+], 833 (9) [M+H-{Sugar A}+Na+], 811 (5) [M+H
35

HR-FAB m/z [M+Na+]: calculated, 963.3804; obtained,
963.3793. UV/Vis (Methanol) kmax (e): 430 (10,200), 316

NMR and MS analysis of deoliosyl-demycarosyl-3C-[3-D

(6400), 281 (50,400), 231 (11,000) nm. IR (KBr) v: 3421
40

m/z (relative intensity): 939 (100) [M—H]. Positive ESI-MS
m/z (relative intensity): 963 (100) [M+Na+], 979 (10)

syl-MTM (formula XIII), C46H66OZO. Amorphous yellow

[M+H-{sugarA}], 535 (9) [M+H-{Trisaccharide}], 421 (12)
[M+H-{Tri- and monosaccharide}]. HR-FAB m/z [M+Na+]:

[M+K+], 833 (10) [M+Na+-{Sugar A}], 703 (50) [M+H
45

{disaccharide}], 443 (12) [aglycon+Na+]. HR-FAB m/z
[M+Na+]: calculated, 939.3849; obtained, 939.3867. UV/Vis
(Methanol) kmax (e):430 (10,600), 3 17 (6800), 281 (49,500),
230 (10,000) nm. IR (KBr) v: 3431 (OH), 2926 (CH), 2851

(CH), 1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1121,
50

calculated, 961.4053; obtained, 961.4045. UV/Vis (Metha
nol) kmax (e):430 (10,500), 316 (6,500), 281 (48,400), 230
(12,600). IR (KBr) v: 3425 (OH), 2928 (CH), 2850 (CH),
1716 (C:O), 1631 (C:O), 1514 (C:C), 1374, 1122, 1064
cm_l. Table 6 shows the 1H-NMR and l3C-NMR data.

boivinosyl-MTM (formula XVII), C45H64OZI. Amorphous
yellow solid. [0t]st —22 (c 0.029, MeOH); Negative ESI-MS

1514 (C:C), 1374, 1122, 1064 cm_l. Table 5 shows the
1H-NMR and 13C-NMR data.
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto

solid. [0t]25D —22 (c 0.027, MeOH); Negative ESI-MS m/z
(relative intensity): 937 (100) [M—H], 973/975 (23) [M+Cl'],
823 (10) [M—H-{sugar A}]. Positive ESI-MS m/z (relative
intensity): 961 (100) [M+Na+], 977 (15) [M+K+], 825 (10)

VIII). The products were characterized by HPLC-MS, as

described in Example 2. The compound demycarosyl-3D-[3
D-digitoxosyl-MTM (formula VIII) is characterized in
Example 2.

{Disaccharide}+Na], 421 (15) [M+H-{bis-disaccharide}].

(OH), 2924 (CH), 2850 (CH), 1716 (C:O), 1631 (C:O),

(pH:7) and after each puri?cation, the samples were diluted
4 times with water, desalted, concentrated and lyophilized.
The following yield was obtained: 3 mg of deoliosyl-demy

carosyl-3C-[3-D-boivinosyl-MTM (formula XVII) and 6.9
mg of demycarosyl-3D-[3-D-digitoxosyl-MTM (formula

m/z (relative intensity): 963 (100) [M+Na+], 979 (10)
sugar A], 681 (20) [M+H-{disaccharide}], 703 (8) [M+H

cultures were extracted 3 times with ethyl acetate. The extract
was then subjected to a ?rst chromatography using a uBonda
pak C18 radial compression cartridge. The elution was car
ried out at 10 ml/min using a mixture of acetonitrile and TFA
in water (50: 50) as a mobile phase. A second chromatography
was then carried out in a Sun?re PrepC18 column (10x250
mm, Waters), at 7 ml/min using a mixture of acetonitrile and
0.1% TFA in water (37:63) as a mobile phase. The HPLC
fractions were collected on 0.1M potassium phosphate buffer

1064 cm“. Table 7 shows the 1H-NMR and l3C-NMR data.
EXAMPLE 7

Obtaining the Bacterial Strain Slreplomyces
55

argillaceus M7U1 (pFL845)
The strain Slreplomyces argillaceus M7U1 (pFL845) was

EXAMPLE 5

generated by means of introducing plasmid pFL845 in Strep

Obtaining the Slreplomyces argillaceus (pFL942)
Bacterial Strain

Zomyces argillaceus M7U1. The introduction of the plasmid
60

was carried out by means of protoplast transformation, fol

lowing standard procedures (Kieser et al., Practical Strepto
The strain Slreplomyces argillaceus (pFL942) was gener
ated by means of introducing plasmid pFL942 in Streptomy

myces genetics, The John Innes Foundation, Norwich, Great

Britain, 2000). The strain Slreplomyces argillaceus M7U1
has been previously described (Mol. Gene. Genet. 2001, 264,

ces argillaceus. The introduction of the plasmid was carried

out by means of protoplast transformation, following stan

dard procedures (Kieser et al., Practical Slreplomyces genet
ics, The John Innes Foundation, Norwich, Great Britain,
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827-835). Plasmid pFL845 has been previously described,
and contains a series of genes encoding the biosynthesis of

nucleosidyl diphosphate (NDP)-D-D-amicetose (Chem.

US 8,426,169 B2
19

20

Commun. (Camb). 2005 Mar. 28; (12):1604-6). The strain
Slreplomyces argillaceus M7U1 (pFL845) was deposited on
May 2, 2008 in the Coleccion Espanola de Cultivos Tipo

UV/Vis (Methanol) kmax (e): 430 (10,600), 316 (6500), 280
(49,500), 231 (12,800) nm. IR (KBr) v: 3423 (OH), 2921

(CH), 2850 (CH), 1716 (C:O), 1631 (C:O), 1514 (C:C),

(CECT) [Spanish Type Culture Collection], Universidad de
Valencia, Campus de Burjassot, 46100 Burjassot (Valencia,

1382, 1131, 1064 cm'. Table 9 shows the 1H-NMR and 13C
NMR data.

NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto

Spain) with accession number CECT 7369.

syl-deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digi
toxosyl-MTM (formula XX), C45H6ZOZO.Amorphous yellow

EXAMPLE 8

solid. [0t]st —15 (c 0.024, MeOH); Positive ESI-MS m/Z
Production of 6-dediolivosyl-6-[3-D-amicetosyl-deo

(relative intensity): 947 (25) [M+Na+], 817 (100) [M+Na+
{sugar C}], 795 (12) [M+H-sugar C]. HR-FAB m/Z

liosyl-demycarosyl-3C-[3-D-boivinosyl-MTM (for
mula XVIII); deoliosyl-demycarosyl-3C-[3-D-olivo

[M+Na+]: calculated, 947.3883; obtained, 947.3867. UV/Vis
(Methanol) kmax (e): 430 (10,400), 316 (6500), 281 (48,

syl-3D-[3-D-digitoxosyl-MTM (formula XIX);
6-dediolivosyl-6-[3-D-amicetosyl-deoliosyl-demy
carosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxosyl-MTM

000), 232 (11,900) nm. IR (KBr) v: 3426 (OH), 2928 (CH),

2843 (CH), 1716 (C:O), 1632 (C:O), 1514 (C:C), 1374,

(formula XX) and 6-dediolivosyl-6-[3-D-amicetosyl

1121, 1063 cm'. Table 10 shows the 1H-NMR and l3C-NMR
data.

deoliosyl-3C-[3-D-olivosyl-MTM (formula XXI)

NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto

To purify the novel derivatives of mithramycin produced
by S. argillaceus M7U1 (pFL845), this strain was cultured in
R5A solid medium. 100 Agar plates were uniformly inocu
lated with spores and after 6 days of incubation at 28° C., the

syl-deoliosyl-3C-[3-D-olivosyl-MTM
20

XXI),

Positive ESI-MS m/Z (relative intensity): XXX. HR-FAB m/ Z

[M+Na+]: calculated, 940.39; obtained, XXX. UV/Vis

cultures were extracted 3 times with ethyl acetate. The extract
was then subj ected to a ?rst chromatography using a uBonda

pak C18 radial compression cartridge. The elution was car

(formula

C45H64OZI. Negative ESI-MS m/Z (relative intensity): XXX.
(Methanol) kmax (6): XXX. IR (KBr) v: XXX. Table 11
shows the 1H-NMR and l3C-NMR data.

25

EXAMPLE 9

ried out at 10 ml/min using a mixture of acetonitrile and TFA

in water (50: 50) as a mobile phase. A second chromatography
was then carried out in a Sun?re PrepC18 column (10x250
mm, Waters), at 7 ml/min using a mixture of acetonitrile and
0.1% TFA in water (40:60) as a mobile phase. The HPLC
fractions were collected on 0.1M potassium phosphate buffer

Antitumor activity of demycarosyl-3D-[3-D-digitoxo
30

(pH:7) and after each puri?cation, the samples were diluted
4 times with water, desalted, concentrated and lyophilized.
The following yield was obtained: 1.7 mg of 6-dediolivosyl

6-[3-D-amicetosyl-deoliosyl-demycarosyl-3C-[3-D-boivino

syl-MTM (formula VIII), deoliosyl-3C-(x-L-digi
toxosyl-MTM (formula IX), deoliosyl-3C-[3-D-my
carosyl-MTM (formula X), 3A-deolivosyl-MTM
(formula XI), demycarosyl-MTM (formula XII),
6-dediolivosyl-6-[3-D-amicetosyl-MTM (formula
XIII)
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deoliosyl-demycarosyl-3C-[3-D-boivinosyl-MTM

syl-MTM (formula XVIII), 6.7 mg of deoliosyl-demy

[for

carosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxosyl-MTM

mula QiVII)]; 6-dediolivosyl-6-[3-D-amicetosyl-deoliosyl

(formula XIX), 12.2 mg of 6-dediolivosyl-6-[3-D-amicetosyl

demycarosyl-3C-[3-D-boivinosyl-MTM [formula (XVIII)];
deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxo
syl-MTM [formula (XIX)]; 6-dediolivosyl-6-[3-D-amiceto
syl-deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digi
toxosyl-MTM [formula QiX)], and 6-dediolivosyl-6-[3-D
amicetosyl-deoliosyl-3C-[3-D-olivosyl-MTM
[formula
09(1)]

deoliosyl-demycarosyl-3C-[3-D-olivosyl-3D-[3-D-digitoxo
syl-MTM (formula XX) and 17 mg of 6-dediolivosyl-6-[3-D

amicetosyl-deoliosyl-3C-8-D-olivosyl-MTM
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(formula

XXI). The products were characterized by HPLC-MS, as
described in Example 2.
NMR and MS analysis of 6-dediolivosyl-6-[3-D-amiceto

syl-deoliosyl-demycarosyl-3C-[3-D-boivinosyl-MTM (for
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mula XVIII): C39H54Ol7. Amorphous yellow solid. [0t]st

titatively determined, using a colorimetric type assay, using

—23 (c 0.026, MeOH); Negative ESI-MS m/Z (relative inten
sity): 793 (10%) [M—H], 777 (100%) (M—H20). Positive
ESI-MS m/Z (relative intensity): 795 (25) [M+H], 817 (20)

[M+Na+], 687 (100), [M+H-{sugar A}], 673 (11)
[M+H{sugarA and 1C}], 443 (12) [aglycon+Na]. HR-FAB

the reaction with sulforhodamine B (SRB) according to the

technique described by Faircloth et al. (Journal of?ssue and
50

cells per well) in aliquots of 195 pl of medium, incubating

(50,700), 231 (13,000) nm. IR (KBr) v: 3428 (OH), 2925
55

1374, 1121, 1063 cm“. Table 8 shows the 1H-NMR and
13 C-NMR data.

NMR and MS analysis of deoliosyl-demycarosyl-3C-[3-D

olivosyl-3D-[3-D-digitoxosyl-MTM

(formula

XIX),

C51H74OZ4. Amorphous yellow solid. [0t]st —21 (c 0.020,
MeOH); Negative ESI-MS m/Z (relative intensity): 1069 (20)
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them for 18 hours in medium without added compound, to
allow the cells to adhere to the surface. The compounds to be
assayed were then added, in 5 [11 samples, in a concentration
range from 10 to 10'8 ug/ml, dissolved in DMSO/EtOH
(0.2% in PS buffer).After 48 hours of exposure, the antitumor
effect was measured using the SRB technique: the cells were

?xed adding 50 pl of 50% (w/v) cold trichloroacetic acid and
incubated for 60 minutes at 4° C. The plates were washed with

[M—H]. Positive ESI-MS m/Z (relative intensity): 1071 (48)

[M+H], 1093 (26) [M+Na+], 963 (28) [M+Na+-{monosac
charide}], 833 (16)) [M+Na+-{disaccharide}], 703 (12)
[M+Na+-{Trisaccharide}], 550 (14) [M+Na+-{tetrasaccha

Culture Methods 1988, 11, 201 -205). The results are shown in
Table 5.

96-well microtiter plates were inoculated with cells (5 ><103

m/Z [M+Na+]: calculated, 817.3253; obtained, 817.3238.
UV/Vis (Methanol) kmax (e): 430 (10,800), 316 (6700), 280

(CH), 2850 (CH), 1716 (C:O), 1632 (C:O), 1514 (C:C),

The derivatives of MTM were assayed against a series of
cell lines from tumors. Cell growth and viability were quan

deionized water and dried. 100 pl of SRB solution (0.4% w/v
in 1% acetic acid) were added to each well, and incubated for
10 minutes at room temperature. The non-bound SRB was

ride], 443 (26) [M+H-{Tri- and disaccharide}]. HR-FAB m/ Z

eliminated, washing with 1% acetic acid. The plates were air
dried and the bound dye was dissolved with Tris buffer. Opti

[M+Na+]: calculated, 1093.4462; obtained, 1093.4447.

cal densities were read in an automatic plate spectrophotom
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